Ensol Biosciences Inc.

A140610

KR7140610007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
4,430 ^KRW	+3.50%		-4.11%	-28.78%

2023	Ensol Biosciences Inc. announced that it has received KRW 4.99999995 billion in funding from Humedix Co., Ltd.	CI
2023	Ensol Biosciences Inc. announced that it expects to receive KRW 4.99999995 billion in funding from Humedix Co., Ltd.	CI

Ensol Biosciences Inc. announced that it has received KRW 3 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd.

February 16, 2021

On February 16, 2021, Ensol Biosciences Inc. (XKON:A140610) closed the transaction.

Latest news about Ensol Biosciences Inc.

Ensol Biosciences Inc. announced that it has received KRW 4.99999995 billion in funding from Humedix Co., Ltd.	20/23/20	CI
Ensol Biosciences Inc. announced that it expects to receive KRW 4.99999995 billion in funding from Humedix Co., Ltd.	10/23/10	CI
Ensol Biosciences Inc. announced that it has received KRW 2.93 billion in funding from Gluon Bond Investment Day	09/22/09	CI
Ensol Biosciences Inc. announced that it expects to receive KRW 5 billion in funding from Gluon Bond Investment Day	11/22/11	CI
Ensol Biosciences Inc. announced that it has received KRW 2 billion in funding	04/22/04	CI
Ensol Biosciences Inc. announced that it expects to receive KRW 2 billion in funding	24/21/24	CI
Ensol Biosciences Inc. announced that it has received KRW 3 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd.	16/21/16	CI
Ensol Biosciences Inc. announced that it expects to receive KRW 3 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd.	05/21/05	CI
Ensol Biosciences Inc. announced that it has received KRW 6.9999856 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Samsung Securities Co. Ltd., Investment Arm	15/21/15	CI
Ensol Biosciences Inc. announced that it expects to receive KRW 6.9999856 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Samsung Securities Co. Ltd., Investment Arm	08/21/08	CI
Ensol Biosciences Inc. announced that it has received KRW 10.999926 billion in funding	30/19/30	CI
Ensol Biosciences Inc. announced that it expects to receive KRW 10.999926 billion in funding	22/19/22	CI

Ensol Biosciences Inc. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved in the development and sale of drugs for degenerative disc disease (DDD), osteoarthritis, triple negative breast cancer (TNBC), Alzheimer's disease (AD) and type I diabetes. In addition, it also produces and sells drugs for animal and provides bio big data analysis services. The drugs for Animal include drugs for animal osteoarthritis, as well as animal anticancer, among others. The bio big data analysis services are provided by knowledge-based in silico drug discovery (KISDD) platform and Ensol trans-omics network system (ETONS).

Sector

Biotechnology & Medical Research

Calendar

28/05/2024 - Investor Meeting

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENSOL BIOSCIENCES INC.	-28.78%	2.8Cr
VERTEX PHARMACEUTICALS INCORPORATED	+7.38%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.13%	11TCr
BIONTECH SE	-12.46%	2.22TCr
ARGENX SE	+0.44%	2.13TCr
GENMAB A/S	-4.18%	1.9TCr
WUXI APPTEC CO., LTD.	-37.85%	1.85TCr
BEIGENE, LTD.	-8.79%	1.68TCr
SAREPTA THERAPEUTICS, INC.	+37.54%	1.25TCr
LEGEND BIOTECH CORPORATION	-24.36%	808.97Cr

Bio Therapeutic Drugs